TABLE 2.
CHARACTERISTICS OF THE ENTIRE STUDY POPULATION AND BY GENOTYPE AT THE BEGINNING OF SALMETEROL TREATMENT PERIOD (VISIT 2)
| Study Population (n = 26) | Arg16Arg (n = 12) | Gly16Gly (n = 14) | P Value* | |
|---|---|---|---|---|
| FEV1 preexercise, % predicted | 82.0 ± 1.8 | 79.9 ± 2.6 | 83.8 ± 2.5 | 0.29 |
| Morning PEF, L/min | 406.4 ± 20.2 | 370.4 ± 22.2 | 439.6 ± 31.2 | 0.08 |
| ACQ | 1.2 ± 0.1 | 1.3 ± 0.2 | 1.1 ± 0.2 | 0.31 |
| FeNO, ppb | 53.3 ± 6.8 | 47.6 ± 9.4 | 58.2 ± 9.9 | 0.44 |
| FEV1 9 h after salmeterol, % predicted | 91.3 ± 1.9 | 90.5 ± 2.5 | 92.0 ± 2.9 | 0.70 |
| FEV1 9 h after salmeterol, % increase from preexercise | 9.3 ± 1.2 | 10.5 ± 1.7 | 8.2 ± 1.7 | 0.35 |
| Max FEV1 % fall after exercise | 8.1 ± 1.2 | 7.6 ± 1.6 | 8.6 ± 1.7 | 0.68 |
| % Bronchoprotection | 70.3 ± 4.1 | 69.6 ± 7.0 | 70.9 ± 5.0 | 0.87 |
Definition of abbreviations: ACQ = asthma control questionnaire; FeNO = exhaled nitric oxide.
Data are expressed as mean ± SE.
*
Comparison between genotypes.